We determined the effect of MSH3 expression upon cell viability in response to anti-cancer drugs including SN-38, the primary metabolite of the topoisomerase I inhibitor irinotecan, the alkylating and DNA intercalating agent oxaliplatin, and the nucleoside analogue 5-fluorouracil (5-FU). This evidence concerns the gene MSH3 and cancer.